课题基金 / 基金详情

Targeting tubulin isotypes in cancer

Targeting tubulin isotypes in cancer
靶向癌症中的微管蛋白同种型
批准号:
2746679
负责人:
金额:
$0.0万
依托单位:
依托单位国家:
英国
项目类别:
Studentship
财政年份:
2022
资助国家:
英国
项目状态:
未结题
起止时间:
2022 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Tubulins are a family of cellular proteins, including a- and B-tubulin, which go on to form microtubules; microtubules perform a variety of functions in the cell, such as coordinating transport within the cell and regulating cell division. Isotypes exist in both a- and B-tubulins, which can differ in their cellular localisation or level of expression. BIII-tubulin is an example of a tubulin isotype. Since microtubules are able to regulate processes such as cell division, microtubules have become an important target for various chemotherapies and anti-cancer drugs. Many are known to bind to pockets found on both the a- and B-tubulins to induce microtubule stabilisation or depolymerisation in order to halt cell division. For instance, Paclitaxel, otherwise known as Taxol, is a chemotherapeutic drug derived from the pacific yew tree, that binds to a taxane binding pocket located on B-tubulins, inducing microtubule stabilisation. However, it has also now been established that certain tubulin isotypes can become upregulated in cancer cells - BIII-tubulins has been found to be upregulated in breast cancer cells. Moreover, these cells have also shown to be more resistance to drugs such as Paclitaxel, thereby leading to the question of whether specific tubulin isotypes play a role in cancer drug resistance. Furthermore, there is a lack of characterisation on the binding affinities of different tubulin isotypes to cancer drugs. This project aims to determine the binding affinities of tubulin isotypes to cancer drugs, and study how cancer drugs affinity could be improved for different tubulin. In the long term, this may potentially lead to more specific and effective prescription of cancer drugs to patients depending on the expression of tubulin isotypes in cancer cells.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
基于氮杂环融合去氧鬼臼毒素类似物的tubulin/PARP1双靶点抑制剂研究
  • 批准号:
    82373769
  • 项目类别:
    面上项目
  • 资助金额:
    49万元
  • 批准年份:
    2023
  • 负责人:
    殷勇
  • 依托单位:
Acetylatedα-tubulin通过促进突触重建以增强偏瘫后康复疗效的作用与机制
GFPT2调控Tubulin多聚谷氨酰胺化促进肺腺癌侵袭转移的机制研究
  • 批准号:
    CSTB2023NSCQ-MSX0081
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2023
  • 负责人:
    王星
  • 依托单位:
β-tubulin/AMPKα互作介导CA4衍生物诱导肿瘤细胞自噬依赖性死亡的机制研究
  • 批准号:
    2023JJ50363
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2023
  • 负责人:
    徐群芳
  • 依托单位: